News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UCB Group’s Cimzia Cuts Arthritis Joint Damage at 16 Weeks
June 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, June 12 (Reuters) - UCB's drug Cimzia stops structural damage to joints in patients with rheumatoid arthritis as soon as 16 weeks after the start of treatment, according to new data presented on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Obesity
Zealand Freezes Mid-Stage Obesity Asset to Focus on More Differentiated Drugs
November 13, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
November 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker
MASH
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb
November 12, 2025
·
2 min read
·
Tristan Manalac
